Medindia
Advertisement

Drug Firm Jubilant Life Sciences Gets ANDA Approval for Generics Mycophenolate Mofetil and Rizatriptan

by Kalyani Thivakaran on January 6, 2015 at 6:22 PM

 Drug Firm Jubilant Life Sciences Gets ANDA Approval for Generics Mycophenolate Mofetil and Rizatriptan
The Indian drug company, Jubilant Life Sciences, has announced in a statement that it has received final approvals for its generics Mycophenolate Mofetil, an immuno-suppressant, and Rizatriptan, used for treatment of migraine, from the Food and Drug Administration (FDA) of the U.S., in the American market.

The drug firm has received final approvals for its Abbreviated New Drug Application (ANDA) for Mycophenolate Mofetil capsules and tablets, manufactured by the company's U.S. subsidiary branch, Jubilant Cadista Pharmaceuticals Inc., and Rizatriptan tablets made at Jubilant Generics Ltd, Jubilant Life Sciences said in a filing to the Bombay Stock Exchange.
Advertisement

The approvals are provided for Mycophenolate Mofetil in the strengths of 250 mg capsules and 500 mg tablets. For Rizatriptan tablets, the strengths of 5 mg and 10 mg were given approval. Mycophenolate Mofetil is a generic version of Roche's Cellcept while Rizatriptan tablets are generics of Merck's Maxalt tablets.

In a statement released by the Jubilant Life Sciences, it was said that, "The current annualised US market size for Mycophenolate Mofetil USP, 250 mg capsules and 500 mg tablets, is $245 million and for Rizatriptan Tablets 5 mg and 10 mg it is $70 million, as per IMS."

The company had a total of 781 filings for formulations as of September 30, 2014, of which 322 have been approved in various regions globally. This includes 72 ANDAs filed in the US and 46 dossier filings in Europe, the company said.

Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
'Hybrid Immunity' may Help Elude COVID-19 Pandemic
Stroop Effect
Plant-Based Diet may Reduce the Risk of COVID-19
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Chronic Renal Failure Drug Toxicity Glomerulonephritis Signature Drug Toxicity 

Recommended Reading
FDA Nods Functional Assessment Technology from Imbio: Boon for COPD
The University of Michigan had developed a new technology 'Functional Assessment Technology', which ...
LightMix Ebola Zaire Test Gets Approval from US FDA
The Swiss pharmaceutical firm Roche has received an emergency authorization from the US Food and ......
FDA's Prescription Guideline Forces Doctors to Write More Legibly
The Indian Medical Association (IMA) has directed all doctors practicing in Maharashtra to follow .....
Clinical Trials - Different Phases of the trial
Clinical trials serve as a vital component for improving the treatment of medical conditions as ......
Chronic Renal Failure
Chronic renal failure or chronic kidney disease is progressive loss in kidney function. The change i...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Glomerulonephritis
Glomerulonephritis is used to describe several kidney disease that damage the glomeruli. Glomerulone...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use